Novo Nordisk CagriSema Outperforms Tirzepatide 5 mg for Weight Loss

Novo Nordisk reported that its investigational CagriSema combination achieved 12.4% average weight loss compared with 9.1% for tirzepatide 5 mg in the Phase 3 REIMAGINE 5 trial. The study evaluated adults with type 2 diabetes whose condition remained inadequately controlled with metformin, an SGLT2 inhibitor or both.

The result gives CagriSema a new position in the rapidly developing market for obesity and diabetes medicines. For chemical traders, pharmaceutical suppliers and procurement teams, the development also highlights the growing manufacturing ecosystem around advanced injectable therapies and the materials required to support their production.

CagriSema's Latest Phase 3 Weight Loss Results

CagriSema combines two active pharmaceutical components, cagrilintide and semaglutide, into a once-weekly injectable treatment. Novo Nordisk is developing the combination for adults with overweight or obesity and for adults with type 2 diabetes.

In REIMAGINE 5, researchers compared CagriSema 1.0 mg/1.0 mg with tirzepatide 5 mg over 60 weeks. CagriSema achieved an estimated average weight loss of 12.4%, compared with 9.1% for tirzepatide, while also producing a non-inferior reduction in HbA1c.

The HbA1c results showed a reduction of 1.71% with CagriSema versus 1.67% with tirzepatide. The findings therefore covered both weight management and blood glucose control, two major areas of pharmaceutical development in metabolic disease.

How CagriSema Works as a Combination Therapy

CagriSema brings together two different biological mechanisms. Cagrilintide acts as a long-acting amylin receptor agonist, while semaglutide acts as a GLP-1 receptor agonist.

The combination reflects a broader pharmaceutical development strategy that uses complementary pathways to address complex metabolic conditions. Rather than relying on a single mechanism, researchers are investigating whether combined activity can produce stronger or more consistent therapeutic effects.

Semaglutide already forms the active ingredient in Novo Nordisk's established obesity and diabetes medicines. Cagrilintide adds another mechanism to the combination, creating a next-generation candidate that the company is positioning within its wider metabolic disease pipeline.

For suppliers, this development also demonstrates how combination medicines can create increasingly sophisticated manufacturing requirements. Production may involve multiple active pharmaceutical ingredients, specialized formulation processes, analytical testing and stringent quality controls.

REIMAGINE 5 and the Pharmaceutical Market Signal

REIMAGINE 5 was designed as a Phase 3 trial involving adults with type 2 diabetes whose condition was inadequately controlled despite treatment with metformin, an SGLT2 inhibitor or both. The trial used two primary endpoints, change in HbA1c and relative change in body weight at Week 60.

The CagriSema result adds to earlier evidence from the company's broader development program. In another Phase 3 study, REIMAGINE 2, CagriSema demonstrated superior weight loss and HbA1c reduction compared with semaglutide across the tested doses.

Novo Nordisk has also reported substantial weight reduction in REDEFINE 1, a Phase 3 study involving people with obesity or overweight. That trial reported 22.7% weight loss after 68 weeks using the trial product estimand for CagriSema at the 2.4 mg/2.4 mg dose.

What CagriSema Means for Pharmaceutical Supply Chains

The expansion of advanced obesity and diabetes therapies can influence procurement requirements across the pharmaceutical manufacturing chain. Demand does not come only from active ingredients. Drug development and production depend on a wider network of excipients, processing materials, laboratory chemicals, packaging components and quality-control inputs.

For chemical suppliers, several areas deserve close attention:

• Pharmaceutical-grade excipients: Injectable medicines require materials that meet strict purity and quality specifications. Suppliers must maintain consistent specifications and reliable documentation.

• Analytical materials: Development programs require extensive testing to assess identity, purity, stability and product performance. This supports demand for specialized laboratory and analytical inputs.

• Process chemicals: Pharmaceutical manufacturing facilities use controlled chemical inputs for cleaning, processing and other production activities.

• Packaging materials: Injectable medicines require specialized primary and secondary packaging systems that protect product integrity throughout storage and distribution.

• Cold-chain support: Biologic and peptide-based medicines can require carefully controlled storage and transportation conditions, increasing the importance of dependable logistics.

A successful clinical program can eventually increase manufacturing activity, but procurement teams must monitor regulatory and commercial milestones before translating trial results into specific purchasing forecasts.

Why Obesity Drug Development Is Expanding

The commercial importance of obesity medicines has encouraged pharmaceutical companies to invest heavily in new mechanisms, formulations and combination therapies. Developers are competing on factors that include weight reduction, glucose control, tolerability, dosing convenience and treatment flexibility.

CagriSema represents one approach to this evolving market. Its fixed-dose combination brings cagrilintide and semaglutide into a single once-weekly treatment, while other companies continue to develop alternative incretin-based therapies and next-generation metabolic medicines.

The competition creates a larger ecosystem for pharmaceutical manufacturers and suppliers. As companies advance multiple candidates through clinical development, they may require additional production capacity, laboratory resources and specialized materials.

Procurement Priorities for Advanced Injectable Medicines

The growth of complex injectable medicines creates specific challenges for buyers. Procurement teams need to look beyond headline pricing because pharmaceutical customers often prioritize quality, continuity and documentation when selecting suppliers.

Material qualification should remain a central purchasing consideration. Suppliers need specifications and quality documentation that allow pharmaceutical manufacturers to evaluate and approve materials for their intended applications.

Supply continuity also matters. A shortage of a seemingly secondary production input can disrupt a highly controlled manufacturing process, making supplier reliability an important part of procurement planning.

Traceability provides another layer of protection. Buyers can benefit from maintaining clear information about manufacturing origin, batch details, specifications and relevant quality records.

Logistics capability becomes particularly important when materials or finished products require controlled storage conditions. Procurement teams should assess whether suppliers can support the required transportation and handling standards.

These considerations create opportunities for chemical distributors that can combine competitive commercial terms with dependable technical and documentation support.

CagriSema and the Competitive Tirzepatide Landscape

The REIMAGINE 5 result provides a direct comparison between CagriSema and tirzepatide at a 5 mg dose. Novo Nordisk reported 12.4% average weight loss with CagriSema compared with 9.1% with tirzepatide at Week 60.

The specific dose and study population matter when interpreting the commercial significance of the result. The trial involved adults with type 2 diabetes, and the comparison used tirzepatide 5 mg rather than the highest doses evaluated in other tirzepatide development programs.

Earlier in 2026, Novo Nordisk reported results from REDEFINE 4, an open-label Phase 3 trial that compared higher-dose CagriSema with tirzepatide 15 mg in people with obesity. CagriSema did not meet that study's primary endpoint for non-inferiority, highlighting the importance of considering the dose, population and trial design when assessing individual clinical results.

For pharmaceutical procurement professionals, this broader development history provides useful context. A single trial result can signal progress, but future manufacturing requirements depend on the full clinical and regulatory pathway.

Regulatory Progress and Manufacturing Outlook

Novo Nordisk submitted a New Drug Application to the U.S. Food and Drug Administration for CagriSema for weight management in December 2025. The company expects an FDA decision in the fourth quarter of 2026.

Regulatory progress represents an important transition point for supply chain planning. If a medicine moves closer to commercialization, pharmaceutical manufacturers may need to prepare larger production volumes and establish dependable supply arrangements for critical inputs.

For chemical traders, this creates an opportunity to monitor pharmaceutical pipelines before commercial demand reaches full scale. Companies that understand the development cycle can evaluate supplier capacity, quality documentation and logistics capabilities well ahead of potential volume increases.

The timing of procurement activity can also vary significantly between clinical programs. Some materials may experience increased demand during development and scale-up, while others may become more relevant only after commercial manufacturing begins.

What Buyers Should Monitor Through 2027

CagriSema's continued development will remain an important signal for suppliers serving the pharmaceutical and biotechnology sectors. Buyers can follow several indicators to understand how the program may affect future supply requirements.

• Regulatory decisions: Approval milestones can indicate when a clinical program may move toward broader commercial manufacturing.

• Manufacturing investment: New facilities, capacity expansions and technology investments can provide clues about future production requirements.

• Clinical program expansion: Additional studies can increase demand for research, analytical and development-related materials before commercial production begins.

• Dose and formulation development: Changes in formulation or manufacturing strategy can alter the specifications and quantities of required inputs.

• Market access: Commercial launches across different regions can create new logistics and sourcing requirements as distribution networks expand.

These indicators can help procurement teams distinguish between short-term clinical demand and longer-term commercial opportunities. They also allow traders to prepare supplier networks before demand becomes more concentrated.

What Pharmaceutical Procurement Teams Should Do Now

CagriSema's latest Phase 3 results add another important development to the rapidly evolving metabolic disease market. Novo Nordisk reported superior weight loss versus tirzepatide 5 mg in REIMAGINE 5, alongside a non-inferior HbA1c reduction, while the broader CagriSema program continues to generate clinical data across obesity and type 2 diabetes populations.

For procurement teams, the practical priority is to monitor the transition from clinical development to regulatory review and potential commercialization. Maintaining qualified suppliers, reviewing pharmaceutical-grade specifications and strengthening logistics capabilities can help companies respond as manufacturing requirements develop.

Chemical traders and distributors can also use pharmaceutical pipeline activity as part of broader market intelligence. CagriSema illustrates how advances in drug development can generate requirements across active ingredients, excipients, laboratory chemicals, processing materials, packaging and specialized supply services.

The development of next-generation metabolic medicines is likely to keep pharmaceutical manufacturing supply chains under close attention as companies compete to expand treatment options and production capabilities. Ready to source Refined Glycerine 99.7% Min USP BP from verified global suppliers? Explore competitive offers on our platform today.